Global Acetyl-Coa Carboxylase Inhibitors Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Firsocostat: Gilead Sciences & Clesacostat: Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Acetyl-Coa Carboxylase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Acetyl-CoA carboxylase inhibitors – Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Acetyl-CoA carboxylase inhibitors Emerging Drugs Chapters

This segment of the Acetyl-CoA carboxylase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acetyl-CoA carboxylase inhibitors Emerging Drugs

Firsocostat: Gilead Sciences

Firsocostat is being developed by Gilead Sciences for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinical trials.

Clesacostat: Pfizer

Clesacostat is an Acetyl-CoA carboxylase inhibitor developed by Pfizer for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinical trials.

Acetyl-CoA carboxylase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Acetyl-CoA carboxylase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Acetyl-CoA carboxylase inhibitors

There are approx. 3+ key companies which are developing the Acetyl-CoA carboxylase inhibitors. The companies which have their Acetyl-CoA carboxylase inhibitors drug candidates in the most advanced stage, i.e. phase II include, Gilead Sciences.

Phases

• Late-stage products
• Mid-stage products
• Early-stage products
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acetyl-CoA carboxylase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acetyl-CoA carboxylase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetyl-CoA carboxylase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetyl-CoA carboxylase inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acetyl-CoA carboxylase inhibitors R&D. The therapies under development are focused on novel approaches for Acetyl-CoA carboxylase inhibitors.

Acetyl-CoA carboxylase inhibitors Report Insights

• Acetyl-CoA carboxylase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acetyl-CoA carboxylase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Acetyl-CoA carboxylase inhibitors drugs?
• How many Acetyl-CoA carboxylase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Acetyl-CoA carboxylase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acetyl-CoA carboxylase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acetyl-CoA carboxylase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gilead Sciences
• Pfizer
• Akanocure Pharmaceuticals
• Novo Nordisk

Key Products

• Firsocostat
• Clesacostat
• AK 1225

Research Programme: acetyl CoA carboxylase 1/2 allosteric inhibitors

• GS 834356

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ueic37

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900